Change in Glycemic Control With Use of a Digital Therapeutic in Adults With Type 2 Diabetes: Cohort Study
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND Intensive lifestyle change can treat and even reverse type 2 diabetes. Digital therapeutics have the potential to deliver lifestyle as medicine for diabetes at scale. OBJECTIVE This 12-week study investigates the effects of a novel digital therapeutic, FareWell, on hemoglobin A1c (HbA1c) and diabetes medication use. METHODS Adults with type 2 diabetes and a mobile phone were recruited throughout the United States using Facebook advertisements. The intervention aim was to effect a sustainable shift to a plant-based dietary pattern and regular exercise by advancing culinary literacy and lifestyle skill acquisition. The intervention was delivered by an app paired with specialized human support, also delivered digitally. Health coaching was provided every 2 weeks by telephone, and a clinical team was available for participants requiring additional support. Participants self-reported current medications and HbA1c at the beginning and end of the 12-week program. Self-efficacy related to managing diabetes and maintaining dietary changes was assessed via survey. Engagement was recorded automatically through the app. RESULTS We enrolled 118 participants with a baseline HbA1c >6.5%. Participants were 81.4% female (96/118) and resided in 38 US states with a mean age of 50.7 (SD 9.4) years, baseline body mass index of 38.1 (SD 8.8) kg/m2, and baseline HbA1c of 8.1% (SD 1.6). At 12 weeks, 86.2% (94/109) of participants were still using the app. Mean change in HbA1c was –0.8% (97/101, SD 1.3, P<.001) for those reporting end-study data. For participants with a baseline HbA1c >7.0% who did not change medications midstudy, HbA1c change was –1.1% (67/69, SD 1.4, P<.001). The proportion of participants with an end-study HbA1c <6.5% was 28% (22/97). After completion of the intervention, 17% (16/97) of participants reported a decrease in diabetic medication while 8% (8/97) reported an increase. A total of 57% (55/97) of participants achieved a composite outcome of reducing HbA1c, reducing diabetic medication use, or both; 92% (90/98) reported greater confidence in their ability to manage their diabetes compared to before the program, and 91% (89/98) reported greater confidence in their ability to maintain a healthy dietary pattern. Participants engaged with the app an average of 4.3 times per day. We observed a significantly greater decrease in HbA1c among participants in the highest tertile of app engagement compared to those in the lowest tertile of app engagement (P=.03). CONCLUSIONS Clinically meaningful reductions in HbA1c were observed with use of the FareWell digital therapeutic. Greater glycemic control was observed with increasing app engagement. Engagement and retention were both high in this widely distributed sample.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Lifestyle therapy has been shown to outperform pharmacotherapy in diabetes prevention [20,21] although the challenge of translating that result to real-world populations persists [22,23].”
BackgroundZhou, B., Lu, Y., Hajifathalian, K., Bentham, J., Di Cesare, M., Danaei, G., Bixby, H., Cowan, M., Ali, M., Taddei, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00618-8 · Cited by 4,311
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Colberg, S. R., Sigal, R. J., Fernhall, B., Regensteiner, J. G., Blissmer, B. J., Rubin, R. R., Chasan-Taber, L., Albright, A. L., & Braun, B. (2010) · Diabetes Care · doi:10.2337/dc10-9990 · Cited by 1,955
Prevention and management of type 2 diabetes: dietary components and nutritional strategies
Ley, S. H., Hamdy, O., Mohan, V., & Hu, F. B. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60613-9 · Cited by 1,301
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164 · cited 1×
“This is important because many situations that are not conducive to long-term health can ameliorate glycemic measures in the short term, among them starvation and serious infectious disease [38].”
BackgroundHow do we define cure of diabetes?
Buse, J. B., Caprio, S., Cefalu, W. T., Ceriello, A., Del Prato, S., Inzucchi, S. E., McLaughlin, S., Phillips, G. L., Robertson, R. P., Rubino, F., et al. (2009) · Diabetes Care · doi:10.2337/dc09-9036 · Cited by 1,003
Michie, S., Yardley, L., West, R., Patrick, K., & Greaves, F. (2017) · Journal of Medical Internet Research · doi:10.2196/jmir.7126 · Cited by 865 · cited 1×
“It was then redeveloped as a native app for Android and iOS using human-centered software design principles [28] and subject to basic usability testing prior to the start of this study.”
Method
Cited by
Challenges in Participant Engagement and Retention Using Mobile Health Apps: Literature Review
Amagai, S., Pila, S., Kaat, A. J., Nowinski, C. J., & Gershon, R. C. (2022) · Journal of Medical Internet Research · doi:10.2196/35120 · Cited by 343
“Refer to Figure 1 for the study selection flowchart and Multimedia Appendix 1 [4-8,17-73] for characteristics of the studies.”
BackgroundArtificial Intelligence: The Future for Diabetes Care
Ellahham, S. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.03.033 · Cited by 373
Digital health technologies: opportunities and challenges in rheumatology
Solomon, D. H., & Rudin, R. S. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0461-x · Cited by 228
Digital Care for Chronic Musculoskeletal Pain: 10,000 Participant Longitudinal Cohort Study
Bailey, J. F., Agarwal, V., Zheng, P., Smuck, M., Fredericson, M., Kennedy, D. J., & Krauss, J. (2020) · Journal of Medical Internet Research · doi:10.2196/18250 · Cited by 109
(2021) · doi:10.2196/29512 · Cited by 91
Metadata
- Authors
- Berman, M. A., Guthrie, N. L., Edwards, K. L., Appelbaum, K. J., Njike, V. Y., Eisenberg, D. M., & Katz, D. L.
- Venue
- JMIR Diabetes
- Publisher
- JMIR Publications Inc.
- Published
- 2018-02-14
- Volume
- 3
- Issue
- 1
- Pages
- e4
- ISSN
- 2371-4379 (ISSN-L)
- OpenAlex
- W2787038658
- Cited by
- 67
- References
- 17
- FWCI
- 10.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Change in Glycemic Control With Use of a Digital Therapeutic in Adults With Type 2 Diabetes: Cohort Study. https://app.cochat.ai/papers/10.2196/diabetes.9591
- The paper
- Berman, M. A., Guthrie, N. L., Edwards, K. L., Appelbaum, K. J., Njike, V. Y., Eisenberg, D. M., & Katz, D. L. (2018). Change in Glycemic Control With Use of a Digital Therapeutic in Adults With Type 2 Diabetes: Cohort Study. JMIR Diabetes. https://doi.org/10.2196/diabetes.9591
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.